/
FBIO
$2.95+$0.19 (+6.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$91.7M
33M shares
52-week range
$1.75 – $4.53
43% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
8.83%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-50.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26.9M | $36.6M | $45.6M | $68.8M | $75.7M | $84.5M | $57.7M | $63.3M |
| Cost of revenue | $6.1M | $10.5M | $14.6M | $32.1M | $30.8M | $22.9M | $20.9M | $20.9M |
| Gross profit | $20.8M | $26.1M | $31.0M | $36.7M | $45.0M | $61.6M | $36.8M | $42.3M |
| Gross margin | 77.2% | 71.2% | 68.0% | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| R&D | $87.4M | $81.3M | $64.1M | $128.9M | $134.9M | $106.1M | $56.9M | $11.9M |
| Operating income | −$120.0M | −$110.8M | −$94.3M | −$188.5M | −$203.6M | −$142.3M | −$110.4M | −$70.2M |
| EBITDA | −$118.4M | −$88.5M | −$87.8M | −$146.2M | −$193.7M | −$135.7M | −$104.5M | −$20.2M |
| Net income | −$84.1M | −$40.0M | −$46.5M | −$64.7M | −$86.6M | −$60.6M | −$46.0M | $6.8M |
| Net margin | -313.0% | -109.1% | -102.0% | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (diluted) | -29.04 | -10.95 | -9.75 | -11.85 | -14.55 | -8.47 | -2.69 | -0.07 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $80M | $2.40 | $2.33–$2.47 | 1 |
| 2027 | $123M | $-0.50 | $-0.52–$-0.48 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Fortress Biotech, Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
www.fortressbiotech.com- Employees
- 78
- IPO / List date
- Nov 17, 2011
- HQ
- BAY HARBOR ISLANDS, FL
Held by traders on TradeandTell
No one on the platform currently holds FBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 99,590 | $277.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-10-10 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded FBIO yet.
